

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM701376

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	RELEASE OF NOTICE OF GRANT OF SECURITY INTEREST IN TRADEMARKS AT REEL/FRAME NO. 6518/0912		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
HCR COLLATERAL MANAGEMENT, LLC		01/05/2022	Limited Liability Company: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	COHERUS BIOSCIENCES, INC.		
<b>Street Address:</b>	333 TWIN DOLPHIN DRIVE, SUITE 600		
<b>City:</b>	REDWOOD CITY		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94065		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>Name:</b>	COHERUS INTERMEDIATE CORP.		
<b>Street Address:</b>	333 TWIN DOLPHIN DRIVE, SUITE 600		
<b>City:</b>	REDWOOD CITY		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94065		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>Name:</b>	INTEKRIN THERAPEUTICS INC.		
<b>Street Address:</b>	555 BRYANT STREET, SUITE 266		
<b>City:</b>	PALO ALTO		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94301		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 9</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	86731676	AQUELXIS	
<b>Serial Number:</b>	86731681	CLEPRYN TA	
<b>Serial Number:</b>	86731687	CLEPRYN ZA	
<b>Serial Number:</b>	86731660	COHERUS	
<b>Serial Number:</b>	86731666	COHERUS BIOSCIENCES	
<b>Serial Number:</b>	86731667		

OP \$240.00 86731676

Property Type	Number	Word Mark
Serial Number:	87307045	EQUAMIRA
Serial Number:	87333213	SYMEXITY
Serial Number:	86731671	UDENYCA

**CORRESPONDENCE DATA**

**Fax Number:**

*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*

**Email:** ipdocket@lw.com

**Correspondent Name:** LATHAM & WATKINS LLP

**Address Line 1:** 650 Town Center Drive, 20th Fl

**Address Line 4:** Costa Mesa, CALIFORNIA 92708

<b>NAME OF SUBMITTER:</b>	KRISTIN J AZCONA
<b>SIGNATURE:</b>	/KJA/
<b>DATE SIGNED:</b>	01/11/2022

**Total Attachments: 7**

- source=HCR-Coherus - Term Loan Payoff - Trademark Release Executed\_128687640\_4\_0#page1.tif
- source=HCR-Coherus - Term Loan Payoff - Trademark Release Executed\_128687640\_4\_0#page2.tif
- source=HCR-Coherus - Term Loan Payoff - Trademark Release Executed\_128687640\_4\_0#page3.tif
- source=HCR-Coherus - Term Loan Payoff - Trademark Release Executed\_128687640\_4\_0#page4.tif
- source=HCR-Coherus - Term Loan Payoff - Trademark Release Executed\_128687640\_4\_0#page5.tif
- source=HCR-Coherus - Term Loan Payoff - Trademark Release Executed\_128687640\_4\_0#page6.tif
- source=HCR-Coherus - Term Loan Payoff - Trademark Release Executed\_128687640\_4\_0#page7.tif

**RELEASE OF NOTICE OF GRANT OF SECURITY INTEREST IN TRADEMARKS**

This **RELEASE OF GRANT OF SECURITY INTEREST IN TRADEMARKS**, dated as of January 5, 2022 (“Trademark Release”), is made by HCR Collateral Management, LLC, as the administrative agent (in such capacity, together with its successors and permitted assigns, the “Administrative Agent”) for the Secured Parties (as defined in the Credit Agreement referred to below) (in such capacity, the “Grantee”), in favor of **COHERUS BIOSCIENCES, INC.**, a Delaware corporation, **COHERUS INTERMEDIATE CORP.**, a Delaware corporation, and **INTEKRIN THERAPEUTICS INC.** a Delaware corporation (each, individually, a “Grantor” and, collectively, the “Grantors”).

**WHEREAS**, (i) each Grantor, the Grantee and others are parties to that certain Credit Agreement, dated as of January 7, 2019 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”) and (ii) the Grantors and the Grantee are parties to that certain Notice of Grant of Security Interest in Trademarks (the “Trademark Security Notice”);

**WHEREAS**, pursuant to the terms of the Credit Agreement and the Trademark Security Notice, each Grantor granted to the Grantee for the benefit of the Secured Parties a continuing security interest in all of such Grantor’s right, title and interest in, to and under the Specified Trademark Collateral (as defined below);

**WHEREAS**, the Trademark Security Notice was recorded at the United States Patent and Trademark Office (the “USPTO”) on January 7, 2019 at Reel 006518 and Frame 0912;

**WHEREAS**, the Grantee has agreed to terminate and release its security interest in, to and under the Specified Trademark Collateral and reassign any and all rights in the same to the applicable Grantor; and

**WHEREAS**, capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to them (including by reference to other agreements) in the Credit Agreement or Trademark Security Notice, as applicable.

**NOW, THEREFORE**, in consideration of the premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Grantee hereby agrees as follows:

1. *Release of Security Interest.* The Grantee hereby terminates, releases, relinquishes and discharges fully all mortgages, liens, and security interests granted to the Grantee for the benefit of itself and the other Secured Parties in the following (collectively, the “Specified Trademark Collateral”):

- a. the Trademark registrations and Trademark applications of each Grantor referred to on Schedule A annexed hereto;
- b. all renewals and extensions of the foregoing;

- c. all goodwill of the business connected with the use of, and symbolized by, the foregoing; and
- d. all proceeds of the foregoing, including, without limitation, any and all causes of action which may exist by reason of infringement thereof and any and all damages arising from past, present and future violations thereof;

and reassigns and transfers to the applicable Grantor, without representation, warranty or recourse of any kind, any and all right, title and interest the Grantee may have in, to or under the Specified Trademark Collateral.

2. **Recordation.** The Grantee hereby authorizes each Grantor, or such Grantor's authorized representative(s) (including, without limitation, Latham & Watkins LLP), as the case may be, at such Grantor's sole expense, to record this document with the USPTO and any other applicable governmental office or agency. The Grantee further authorizes and requests that the Commissioner for Trademarks in the USPTO, and any other necessary United States government officer, record this document, it being understood that such recordation shall be at the Grantors' sole expense.

3. **Governing Law.** This document shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York.


4. **Counterparts.** This Trademark Release may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart by facsimile or electronic mail shall be equally effective as delivery of an original executed counterpart.

**[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]**

**IN WITNESS WHEREOF**, the Grantee has caused this Trademark Release to be duly executed as of the date first set forth above.

Grantee:

**HCR COLLATERAL MANAGEMENT, LLC,**  
as Administrative Agent

By:   
Name: Christopher A. White  
Title: President and Chief Financial Officer

Trademark Release

**TRADEMARK**  
**REEL: 007556 FRAME: 0219**




**SCHEDULE A**

(See Attached)


## Schedule 1

## Trademarks and Trademark Applications

Trademark	Serial Number	Filing Date	Registration Number	Registration Date	Class(es)	Goods and Services
AQUELXIS	86/731676	08/20/2015			05	Pharmaceuticals used for stimulating white blood cell production; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of inflammation in Class 5.
CLEPRYNIA	86/731681	08/20/2015			05	Pharmaceuticals used for stimulating white blood cell production; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of inflammation in Class 5.
CLEPRYNZA	86/731687	08/20/2015			05	Pharmaceuticals used for stimulating white blood cell production; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of inflammation in Class 5.
COHERUS	86/731660	08/20/2015			05	Pharmaceuticals in Class 5.
COHERUS	86/731660	08/20/2015			40	Manufacturing services for others in the field of pharmaceutical products in Class 40.
COHERUS	86/731660	08/20/2015			42	Research, development and consulting services in the medical, pharmaceutical research and biotechnology fields; research and development in the medical field in Class 42.
COHERUS	86/731660	08/20/2015			44	Providing information in the fields of health and medicine; consulting services in the field of pharmaceuticals and medical care in Class 44.
COHERUS BIOSCIENCES	86/731666	08/20/2015			05	Pharmaceuticals in Class 5.
COHERUS BIOSCIENCES	86/731666	08/20/2015			40	Manufacturing services for others in the field of pharmaceutical products in Class 40.
COHERUS BIOSCIENCES	86/731666	08/20/2015			42	Research, development and consulting services in the medical, pharmaceutical research and biotechnology fields; research and development in the medical field in Class 42.

Trademark	Serial Number	Filing Date	Registration Number	Registration Date	Class(es)	Goods and Services
COHERUS BIOSCIENCES	86/731666	08/20/2015			44	Providing information in the fields of health and medicine; consulting services in the field of pharmaceuticals and medical care in Class 44.
	86/731667	08/20/2015			05	Pharmaceuticals for use in stimulating white blood cell production, for treating cancer, for treating multiple sclerosis, for treating Huntington's disease, for treating Alzheimer's disease, for treating progressive supranuclear palsy, for treating nonalcoholic steatohepatitis, for treating diseases and disorders of the eye, for treating hematological diseases and disorders, for treating diseases and disorders of the immune system, for treating cardiovascular diseases and disorders, and for treating inflammatory diseases and disorders in Class 5.
Coherus Logo	86/731667	08/20/2015			40	Manufacturing services for others in the field of pharmaceutical products in Class 40.
						
Coherus Logo	86/731667	08/20/2015			42	Research, development and consulting services in the pharmaceutical research and biotechnology fields; research and development in the medical field in Class 42.
						



Trademark	Serial Number	Filing Date	Registration Number	Registration Date	Class(es)	Goods and Services
Coherus Logo 	86/731667	08/20/2015			44	Providing information in the fields of health and medicine; consulting services in the field of pharmaceuticals and medical care in Class 44.
ENBEQUA	79/186490	01/12/2016	1288315	01/12/2016	05	Pharmaceutical preparations for treating human immune diseases and conditions in Class 5.
EQUAMIRA	87/307045	01/19/2017			05	Pharmaceutical preparations for the treatment of autoimmune diseases in Class 5.
SYMEXITY	87/333213	02/13/2017			05	Pharmaceutical preparations for the treatment of autoimmune diseases in Class 5.
UDENNYCA	86/731671	08/20/2015			05	Pharmaceuticals used for stimulating white blood cell production; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for the treatment of inflammation in Class 5.